Phlebopress, capsules 300 mg 30 pcs

A semi-synthetic bioflavonoid (rutin derivative) of benzopyran class, has P-vitamin activity, has venotonic, angioprotective, anti-inflammatory and anti-edema effect, reduces capillary permeability and fragility.

His pharmacodynamic properties are associated with the participation of bioflavonoids of troxerutin in redox processes and hyaluronidase inhibition. Inhibiting hyaluronidase, troxerutin stabilizes hyaluronic acid of cell membranes and reduces their permeability.

It has antioxidant activity, as a result of which it prevents oxidation of ascorbic acid, adrenaline and lipids. In addition, it reduces capillary permeability and fragility and prevents damage to the basal membrane of endothelial cells when various factors are acting on it.

Troxerutin increases the density of the vascular wall, reduces the exudation of the liquid part of the plasma and the diapedesis of the blood cells. Reduces exudative inflammation in the vascular wall by reducing platelet adhesion to its surface. Inhibits aggregation and increases the degree of red blood cell deformation.

The use of troxerutin is possible both in the initial and in the late stages of treatment of chronic venous insufficiency, it is possible to use as one of the components of complex treatment. Troxerutin reduces swelling and heaviness in the legs, decreases the intensity of pain and cramps and improves tissue trophism.

Troxerutin relieves symptoms associated with hemorrhoids (pain, exudation, itching, bleeding).

With its influence on the permeability and resistance of capillary walls, troxerutin helps to slow down the progression of diabetic retinopathy. The effect of troxerutin on the rheological properties of the blood helps to prevent the development of retinal vascular microthrombosis.

Pharmacokinetics

Troxerutin is quickly absorbed when the drug is taken orally. Maximum plasma concentration of troxerutin (Cmax) is established on average 1.75 ± 0.46 hours after oral administration. Absorption is approximately 10-15%. Bioavailability of the drug increases with increasing dose.

The elimination half-life (T1/2) is 6.77 ± 2.37 hours. The therapeutic concentration of the drug in plasma is maintained for 8 hours. In 30 hours after troxerutin administration a second maximum of the drug concentration in plasma is observed due to enterohepatic recirculation.

Partially metabolized in the liver to form glucuronide and trihydroethylquercitin. It is excreted mainly through the intestine (up to 65-70%), a smaller part of the drug (up to 25%) is excreted unchanged by the kidneys.

Indications

The drug Phlebopress® capsules 300 mg is used as part of complex therapy for the following diseases:

• chronic venous insufficiency;

• trophic disorders in chronic venous insufficiency and trophic ulcers;

• varicose veins;

• superficial thrombophlebitis, periphlebitis;

• postthrombotic syndrome;

• post-traumatic swelling and soft tissue hematomas;

• as an auxiliary treatment after sclerotherapy and/or removal of varicose veins of the lower extremities;

• hemorrhoids (to relieve symptoms);

• diabetic angiopathy, retinopathy.

Pharmacological effect

A semi-synthetic bioflavonoid (rutin derivative) of the benzopyran class, has P-vitamin activity, has venotonic, angioprotective, anti-inflammatory and decongestant effects, reduces capillary permeability and fragility.

Its pharmacodynamic properties are associated with the participation of the bioflavonoids troxerutin in redox processes and inhibition of hyaluronidase. By inhibiting hyaluronidase, troxerutin stabilizes hyaluronic acid in cell membranes and reduces their permeability.

It has antioxidant activity, which prevents the oxidation of ascorbic acid, adrenaline and lipids. In addition, it reduces the permeability and fragility of capillaries, prevents damage to the basement membrane of endothelial cells when exposed to various factors.

Troxerutin increases the density of the vascular wall, reduces the exudation of the liquid part of the plasma and the diapedesis of blood cells. Reduces exudative inflammation in the vascular wall, reducing platelet adhesion to its surface. Inhibits aggregation and increases the degree of deformation of red blood cells.

The use of troxerutin is possible both in the initial and late stages of treatment of chronic venous insufficiency; it can be used as one of the components of complex treatment. Troxerutin reduces swelling and a feeling of heaviness in the legs, reduces the intensity of pain and cramps, and improves tissue trophism.

Troxerutin relieves symptoms associated with hemorrhoids (pain, exudation, itching, bleeding).

Due to its effect on the permeability and resistance of capillary walls, troxerutin helps slow the progression of diabetic retinopathy. The effect of troxerutin on the rheological properties of blood helps prevent the development of retinal vascular microthrombosis.

Pharmacokinetics

Troxerutin is rapidly absorbed when the drug is taken orally. The maximum concentration of troxerutin in the blood plasma (Cmax) is established on average 1.75 ± 0.46 hours after oral administration. Absorption is approximately 10-15%. The bioavailability of the drug increases with increasing dose.

The half-life (T1/2) is 6.77 ± 2.37 hours. The therapeutic concentration of the drug in the blood plasma is maintained for 8 hours. 30 hours after taking troxerutin, a second maximum concentration of the drug in the blood plasma is observed, due to enterohepatic recirculation.

Partially metabolized in the liver to form glucuronide and trihydroethylquercetin. It is excreted mainly through the intestines (up to 65-70%), a smaller part (up to 25%) of the drug is excreted unchanged by the kidneys.

Special instructions

There is insufficient experience with the use of Phlebopress® in children under 18 years of age. When treating superficial thrombophlebitis or deep vein thrombosis, the use of the drug does not exclude the need to prescribe anti-inflammatory and antithrombotic therapy.

Phlebopress® is ineffective for edema caused by concomitant diseases of the liver, kidneys and heart.

When using the drug independently, you should not exceed the maximum duration and recommended doses.

If during the period of use of the drug the severity of the symptoms of the disease does not decrease or the symptoms of the disease become more severe, you should immediately consult a doctor.

Impact on the ability to drive vehicles and machinery

Taking the drug Phlebopress® does not affect motor and mental reactions, does not interfere with the control of vehicles and other complex mechanisms.

Active ingredient

Troxerutin

Composition

For 1 capsule:

Active ingredient:

troxerutin – 300.00 mg.

Excipients:

lactose monohydrate (milk sugar) – 39.50 mg;

sodium carboxymethyl starch – 7.00 mg;

magnesium stearate – 3.50 mg.

Contraindications

• hypersensitivity to troxerutin and other components of the drug;

• peptic ulcer of the stomach, duodenum, chronic gastritis in the acute phase;

• lactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome;

• pregnancy (first trimester);

• breastfeeding period;

• children under 18 years of age (experience of use is limited).

With caution:

• Chronic renal failure (with long-term use).

Side Effects

Troxerutin is very well tolerated; in rare cases, mild adverse reactions occur.

Immune system disorders: hypersensitivity reactions.

Nervous system disorders: headache.

Vascular disorders: “flushes” of blood to the face.

Gastrointestinal disorders: nausea, vomiting, stomach pain, flatulence, diarrhea, erosive and ulcerative lesions of the gastrointestinal tract. Skin and subcutaneous tissue disorders: erythema, itching, skin rash.

If any of the side effects indicated in the instructions get worse or you notice any other side effects not listed in the instructions, tell your doctor!

Interaction

When used simultaneously, it enhances the effect of ascorbic acid on the resistance and permeability of the vascular wall.

Overdose

Symptoms. Troxerutin has very low toxicity. In case of an overdose, the following symptoms may appear: agitation, nausea, headache, flushing of blood to the face.

Treatment. It is necessary to rinse the stomach and take activated charcoal (within an hour after administration). If necessary, provide symptomatic and supportive treatment.

In case of overdose, consult a doctor immediately.

Storage conditions

At a temperature not exceeding 25 °C.

Keep out of the reach of children.

Shelf life

3 years.

Do not use after expiration date.

Manufacturer

Ozon, Russia